Biodexa Pharmaceuticals Plc
BDRX
$7.51
-$0.26-3.35%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 51.60K | 104.10K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 51.60K | 104.10K |
| Cost of Revenue | 6.35M | 6.62M | 6.96M | 6.01M | 5.05M |
| Gross Profit | -6.35M | -6.62M | -6.96M | -5.96M | -4.94M |
| SG&A Expenses | 5.36M | 5.05M | 4.84M | 4.18M | 3.50M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -75.10K | -57.10K | -40.10K | -28.90K | -17.60K |
| Total Operating Expenses | 11.64M | 11.62M | 11.77M | 10.16M | 8.53M |
| Operating Income | -11.64M | -11.62M | -11.77M | -10.11M | -8.43M |
| Income Before Tax | -8.44M | -7.95M | -7.63M | -8.25M | -8.89M |
| Income Tax Expenses | -375.40K | -344.00K | -319.40K | -312.70K | -306.10K |
| Earnings from Continuing Operations | -8.06 | -7.61 | -7.31 | -7.94 | -8.59 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.06M | -7.61M | -7.31M | -7.94M | -8.59M |
| EBIT | -11.64M | -11.62M | -11.77M | -10.11M | -8.43M |
| EBITDA | -11.48M | -11.47M | -11.62M | -9.95M | -8.25M |
| EPS Basic | -6.67M | -12.03M | -17.47M | -15.13M | -12.75M |
| Normalized Basic EPS | -43.76 | -78.45 | -113.72 | -98.34 | -82.72 |
| EPS Diluted | -6.67M | -12.03M | -17.47M | -15.13M | -12.75M |
| Normalized Diluted EPS | -43.76 | -78.45 | -113.72 | -98.34 | -82.72 |
| Average Basic Shares Outstanding | 637.80K | 417.90K | 198.00K | 131.80K | 65.60K |
| Average Diluted Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |